ExCrossV Multi Site Trial för vaskulariserad högriskkeratoplastik (ExCrossV)
Multicenter klinisk prövning för att utvärdera säkerheten och effekten av ex vivo korneal tvärbindning av donatorhornhinnevävnad som används för vaskulariserad högriskkeratoplastik
The main objective of this study is to determine the safety of Ex Vivo Cross Linking (CXL) of donor corneal tissue in participants who have undergone high-risk penetrating keratoplasty.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This is a randomized, double-masked, multi site clinical trial to determine the safety of Ex Vivo CXL of donor corneal tissue in 96 participants who have undergone high-risk penetrating keratoplasty.
Participants will be randomized to receive either a corneal tissue that has been untreated vs. a corneal tissue that has been treated with Photrexa® Viscous & Photrexa® and UV light. The tissue will be prepared by a Corneal Tissue Bank under Current-Good-Tissue-Practice (CGTP) and delivered to the respective institutions for transplantation. Participants will be monitored up to 24 months post-transplantation to assess for adverse events of the randomized tissue.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Michael Cheung, MSc, CCRP
- Telefonnummer: 6175736060
- E-post: mcheung0@meei.harvard.edu
Studera Kontakt Backup
- Namn: Nikolay Boychev, OD, PhD
Studieorter
-
-
California
-
Irvine, California, Förenta staterna, 92617
- Har inte rekryterat ännu
- University of California Irvine - Gavin Herbert Eye Institute
-
Huvudutredare:
- Marjan Farid, MD
-
Los Angeles, California, Förenta staterna, 90095
- Har inte rekryterat ännu
- The University of California Los Angeles - Doris Stein Eye Research Center
-
Huvudutredare:
- Anthony Aldave, MD
-
San Francisco, California, Förenta staterna, 94158
- Har inte rekryterat ännu
- University of California San Francisco - Wayne and Gladys Valley Center for Vision
-
Kontakt:
- Beth Cutrer
- E-post: Beth.Cutrer@ucsf.edu
-
Huvudutredare:
- Julie Schallhorn, MD
-
-
Florida
-
Miami, Florida, Förenta staterna, 33136
- Rekrytering
- University of Miami - Bascom Palmer Eye Institute
-
Huvudutredare:
- Guillermo Amescua, MD
-
Kontakt:
- Jeremy Sandoval
- E-post: jxs7997@med.miami.edu
-
Kontakt:
- Javier Parades, MBA, CCRP
- E-post: jxp2537@med.miami.edu
-
-
Indiana
-
Indianapolis, Indiana, Förenta staterna, 46260
- Rekrytering
- Price Vision Group
-
Huvudutredare:
- David Price, MD
-
Kontakt:
- Marianne Price, PhD
- Telefonnummer: 317-844-5530
- E-post: mprice@cornea.org
-
Kontakt:
- Lauren Blisset
- Telefonnummer: (317) 814-2996
- E-post: lauren@cornea.org
-
-
Kansas
-
Overland Park, Kansas, Förenta staterna, 66204
- Rekrytering
- Kansas City Eye Clinic
-
Huvudutredare:
- Christopher Ketcherside, MD
-
Underutredare:
- Megan Haghnegahdar, MD
-
Kontakt:
- Megan Hefer, CCRP
- Telefonnummer: 913-341-3100
- E-post: mhefter@kceyeclinic.com
-
-
Maryland
-
Towson, Maryland, Förenta staterna, 21204
- Rekrytering
- Mid-Atlantic Cornea Consultant
-
Huvudutredare:
- Sudeep Pramanik, MD
-
Huvudutredare:
- Alexander Altman, MD
-
Kontakt:
- Lauren West
- Telefonnummer: 410-616-9952
- E-post: lwest@midatlanticcornea.com
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02114
- Rekrytering
- Massachusetts Eye and Ear
-
Kontakt:
- Nikolay Boychev, OD, PhD
- E-post: nboychev@meei.harvard.edu
-
Huvudutredare:
- Joseph Ciolino, MD
-
Kontakt:
- Michael Cheung, MSc, CCRP
- Telefonnummer: 617-573-6060
- E-post: mcheung0@meei.harvard.edu
-
-
Michigan
-
Ann Arbor, Michigan, Förenta staterna, 48015
- Rekrytering
- University of Michigan - Kellogg Eye Center
-
Huvudutredare:
- Shahzad Mian, MD
-
Kontakt:
- Lianne Shami, BS
- Telefonnummer: 734-647-8397
- E-post: liannes@med.umich.edu
-
-
North Carolina
-
Bermuda Run, North Carolina, Förenta staterna, 27006
- Har inte rekryterat ännu
- Wake Forest Baptist Eye Center
-
Huvudutredare:
- Matthew Giegengack, MD
-
Kontakt:
- Christina Robbins
- Telefonnummer: 336-716-3859
- E-post: Christina.Robbins@Advocatehealth.org
-
Durham, North Carolina, Förenta staterna, 27705
- Rekrytering
- Duke University - Duke Eye Center
-
Huvudutredare:
- Esen Akpek, MD
-
Kontakt:
- Nathan Hamilton
- Telefonnummer: 919-668-0230
- E-post: nathan.hamilton@duke.edu
-
Kontakt:
- Kyle Munar
- E-post: kyle.munar@duke.edu
-
-
Ohio
-
Cincinnati, Ohio, Förenta staterna, 45242
- Rekrytering
- Cincinnati Eye Institute
-
Huvudutredare:
- Kavitha Sivaraman, MD
-
Kontakt:
- Lee Stokes
- Telefonnummer: 513-569-3213
- E-post: lstokes@cvphealth.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Age 18 and older
- Willing and able to provide written informed consent
- Willing and able to comply with study assessments for the full duration of the study
- Patients undergoing high-risk penetrating keratoplasty, defined as corneal neovascularization (NV) in 1 or more quadrants ≥2 mm from the limbus or extension of corneal NV to the graft-host junction in a previously failed graft
- Superficial vessels are defined as those within the anterior one-third of the cornea and deep vessels within the posterior two-thirds of the cornea (i.e., deep stroma).
Superficial CNV involving ≤2 quadrants (equivalent to ≤6 clock hours) without deep CNV are classified as mild. CNV with >2 quadrants of superficial vessels (>6 clock hours) or 1 quadrant of deep vessels (>3 clock hours) as severe (36).
Exclusion Criteria:
- History of Stevens-Johnson syndrome or ocular pemphigoid
- Ocular or periocular malignancy
- Non-healing epithelial defect of at least 0.5x0.5 mm in host corneal bed lasting ≥6 weeks preoperatively
- Uncontrolled glaucoma
- Change in topical corticosteroid regimen within 14 days of transplantation
- Use of systemic immunosuppressive for indication other than corneal graft rejection
- Participation in another simultaneous medical investigation or trial
- Pregnancy (positive pregnancy test) or lactating
- Pre-menopausal women not using adequate contraception (Reliable intrauterine devices, hormonal contraception or a spermicide in combination with a barrier method)
- Ocular infection within 30 days prior to study entry.
- Presence of anterior chamber intraocular lens
- Active uveitis within 90 days prior to the study entry.
- No ocular surgery or procedure within 90 days prior to the study entry or concomitant to the study procedure.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Participants Receiving Treated Cross Linked Corneal Tissue
Participants in this group will receive tissue that has been treated with 0.1% riboflavin (Vitamin B2) and 20% dextran (Photrexa® viscous and Photrexa®) with UV light treatment. Participants will be monitored over a period of 24 months. |
Participants are transplanted with corneal donor tissue that has been treated with 0.1% riboflavin (Vitamin B2) and 20% dextran (Photrexa® Viscous & Photrexa®) with UV light treatment.
Andra namn:
|
|
Placebo-jämförare: Participants Receiving Untreated Cross Linked Corneal Tissue
Participants in this group will receive tissue that has has not been treated with 0.1% riboflavin (Vitamin B2) and 20% dextran (Photrexa® viscous and Photrexa®) without UV light treatment. Participants will be monitored over a period of 24 months. |
Participants are transplanted with corneal donor tissue that has not been treated with the UV light and the 0.1% riboflavin (Vitamin B2) and 20% dextran (Photrexa® Viscous & Photrexa®) without UV light treatment, this is the control group.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Determining the Primary Safety of Corneal Cross Linking
Tidsram: 24 Months
|
The occurrence of adverse events throughout study including:
|
24 Months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Measure of the Frequency of Graft Failures though Corneal Cross Linking
Tidsram: 24 Months
|
To determine the efficacy of using cross linked tissue for the indicated keratoplasty for the prevention of corneal graft rejection and corneal neovascularization, by measuring the frequency of primary graft failures over 24 months. |
24 Months
|
|
Measure of Time from Surgery to Overall Graft Failure for Corneal Cross Linking over 24 Months
Tidsram: 24 Months
|
The efficacy of using cross linked tissue for the indicated keratoplasty for the prevention of corneal graft rejection and corneal neovascularization, by measuring the time from surgery to overall graft failure (regardless of cause). |
24 Months
|
|
Measure of Time from Surgery to Graft Rejection for Corneal Cross Linking over 24 Months
Tidsram: 24 Months
|
The efficacy of using cross linked tissue for the indicated keratoplasty for the prevention of corneal graft rejection and corneal neovascularization, by measuring the occurrence of any rejection episode. (Epithelial, Endothelia, Sub Epithelial, or Mixed) determined as either definite rejection, probably rejection, and possible rejection, from the time of surgery over 24 months. |
24 Months
|
|
Measure of the Efficacy of Corneal Cross Linking Through Image Review
Tidsram: 24 Months
|
The efficacy of using cross linked tissue for the indicated keratoplasty for the prevention of corneal graft rejection and corneal neovascularization. 1. Corneal Neovascularization (CNV) measured and analyzed from slit-lamp photography. |
24 Months
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Joseph Ciolino, MD, Massachusetts Eye and Ear
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 2023P002687
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .